Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report

被引：4
作者：
Kattan, Joseph [1 ]
Kattan, Clarisse [1 ]
Farhat, Fadi [2 ]
Assi, Tarek [2 ,3 ]
机构：
[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
[2] Hammoud Hosp UMC, Hematol Oncol Dept, Saida, Lebanon
[3] St Joseph Univ, Hematol Oncol Dept, Fac Med, Beirut, Lebanon
来源：
ANTI-CANCER DRUGS | 2019年 / 30卷 / 10期
关键词：
binimetinib; BRAF; encorafenib; immune checkpoint; MEK; melanoma; resistance; METASTATIC MELANOMA; MUTANT MELANOMA; OPEN-LABEL; NIVOLUMAB; COMBINATION; DABRAFENIB; TRAMETINIB; IPILIMUMAB; EFFICACY; STANDARD;
D O I：
10.1097/CAD.0000000000000827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The advent of BRAF and MEK inhibitors changed the landscape of the management of BRAF mutated melanoma patients. In this article, we report the case of a 51-year-old man with BRAF mutated locally advanced cutaneous melanoma of the head who demonstrated a limited response to initial anti-BRAF monotherapy followed by extensive surgery. Anti-PD1 therapy failed to reverse the disease progression. However, subsequent double inhibition of the BRAF and MEK pathways induced a fast and remarkable tumour response.
引用
收藏
页码：1052 / 1054
页数：3
相关论文
共 50 条
  • [11] Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
    Queirolo, Paola
    Picasso, Virginia
    Spagnolo, Francesco
    CANCER TREATMENT REVIEWS, 2015, 41 (06) : 519 - 526
  • [12] Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
    Schulz, Alexander
    Raetz, Jennifer
    Karitzky, Paula C.
    Dinter, Lisa
    Tietze, Julia K.
    Kolbe, Isabell
    Kaeubler, Theresa
    Renner, Bertold
    Beissert, Stefan
    Meier, Friedegund
    Westphal, Dana
    CANCERS, 2022, 14 (19)
  • [13] Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma
    Sibaud, Vincent
    Baric, Lilian
    Cantagrel, Alain
    Di Palma, Mario
    Ederhy, Stephane
    Paques, Michel
    Perlemuter, Gabriel
    BULLETIN DU CANCER, 2021, 108 (05) : 528 - 543
  • [14] Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report
    Kass, Samantha L.
    Linden, Allison F.
    Jackson, Patrick G.
    De Brito, Pedro A.
    Atkins, Michael B.
    MELANOMA MANAGEMENT, 2015, 2 (02) : 115 - 120
  • [15] Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
    Hamid, Omid
    Cowey, C. Lance
    Offner, Michelle
    Faries, Mark
    Carvajal, Richard D.
    CANCERS, 2019, 11 (11)
  • [16] Inhibition of BRAF and MEK in BRAF-mutant melanoma
    Smalley, Keiran S. M.
    Sondak, Vernon K.
    LANCET, 2015, 386 (9992) : 410 - 412
  • [17] Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
    Broman, Kristy Kummerow
    Dossett, Lesly A.
    Sun, James
    Eroglu, Zeynep
    Zager, Jonathan S.
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (05) : 381 - 392
  • [18] BRAF and MEK inhibitors in therapy of advanced melanoma
    Kosela, Hanna
    Switaj, Tomasz
    Rutkowski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (05): : 246 - 253
  • [19] Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma
    Niessner, Heike
    Huesch, Anna
    Kosnopfel, Corinna
    Meinhardt, Matthias
    Westphal, Dana
    Meier, Friedegund
    Schilling, Bastian
    Sinnberg, Tobias
    CANCERS, 2023, 15 (23)
  • [20] Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
    Chan, Xian Yang
    Singh, Alamdeep
    Osman, Narin
    Piva, Terrence J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
12345